Publikation

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.

Wissenschaftlicher Artikel/Review - 10.02.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Yaghi S, Shu L, Bakradze E, Omran S, Argilés J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair A, Simpkins A, Trivioli G, Kung J, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman L, Mistry E, Kerrigan D, Lafever H, Nguyen T, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad S, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati M, Paciaroni M, Siegler J, Kamen S, Yu S, Leon Guerrero C, Atallah E, De Marchis G, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022; 53:728-738.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Stroke 2022; 53
Veröffentlichungsdatum
10.02.2022
eISSN (Online)
1524-4628
Seiten
728-738
Kurzbeschreibung/Zielsetzung

A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.